Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LNCaP |
prostate epithelial cancer cells | ATCC CRL-1740 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Ansems et al., The Prostate, 2012, 72: 1708-1717, DOI 10.1002/pros.22522 | |||
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | J. J. Rodgers et al., J. Cell Biochem., 2019, 120:848-860, DOI: 10.1002/jcb.27446 | Link | ||
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | U. K. Mukhopadhyay et al., Cytokine, 2016; 82: 70-79; doi.org/10.1016/j.cyto.2016.01.013 | |||
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene PRO | publication | R. Malaguarnera et al., Endocrinology, 2014, 155(4): 1207-1221, doi: 10.1210/en.2013-1925 | Link | |
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | application note | ![]() |
||
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | U. K. Mukhopadhyay et al., Cancer Res., Apr 2005; 65: 2872 - 2881 | Link | |
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M. Endres et al., Oncotarget, 2016, 7(39): 64244-64259 | Link | |
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | J. Elvenes et al., PLoS ONE, 2011, 6(9): e24659, doi:10.1371/journal.pone.0024659 | Link | |
ME-180 |
Human papillomavirus-related cervical squamous cell carcinoma cell line | ATCC HTB-33 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | E. Xu et al., Mol. Cancer Res., 2014, 12(3):359-369, DOI: 10.1158/1541-7786.MCR-13-0526 | Link | ||
NB-6 |
Chinese Hamster Ovary cell line | Hamster | genital tract | cell line | adherent | oligonucleotide | DOTAP | publication | V. Noé et al., Int. J. Mol. Sci., 2021, 22(7): 3784, doi: 10.3390/ijms22073784 | Link | |||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | oligonucleotide | DOTAP | publication | A. Avinó et al., Protocols in Nucleic Acid Chemistry, 2020, 77: e78, doi: 10.1002/cpnc.78 | |||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | U. K. Mukhopadhyay et al., Cancer Res., Apr 2005; 65: 2872 - 2881 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | oligonucleotide | DOTAP | publication | E. Aubets et al., Int. J. Mol. Sci., 2021, 22(18): 10025, doi: 10.3390/ijms221810025 | Link | ||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | application note | ![]() |
||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | oligonucleotide | DOTAP | publication | M. M. M. Enriquez ez al., PLoSONE13(11):e0206818, doi.org/10.1371/journal.pone.0206818 | Link | ||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
|||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | U. Weirauch et al., Nucleic Acid Therapeutics, 2013, 23 (4): 264-272, DOI: 10.1089/nat.2012.0407 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Harada et al., J. Biol. Chem., Aug 2007; 282: 22651 - 22661 | Link | ||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | C. Morich, Dissertation, 2016, Georg-August University Göttingen | Link | ||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
|||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene SI | publication | M. B. Morelli et al., BMC Cancer, 2014, 14:921, doi:10.1186/1471-2407-14-921 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | S. Steinmann et al., J. Biol. Chem., Vol. 288, No. 31, pp. 22257–22269, August 2, 2013 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | plasmid | Metafectene EASY | publication | J. C. Romero Sandoval, PhD Thesis, 2014, Universitat de Barcelona | Link | ||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | E. Werwein et al., Nucleic Acids Res., 2019, 47(1): 103–121, doi: 10.1093/nar/gky935 | Link | |
PC-3M |
Human prostate carcinoma cell line | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. L. Omara-Opyene et al., Lab Invest., 2004 Jul; 84(7):894-907 |